Combining AAV and Cisplatin for Head and Neck Cancer Treatment
Author Information
Author(s): Jiang Minghong, Liu Zheng, Xiang Yang, Ma Hong, Liu Shilian, Liu Yanxin, Zheng Dexian
Primary Institution: National Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Hypothesis
Can cisplatin enhance the effectiveness of AAV-mediated TRAIL gene therapy in treating head and neck squamous cell carcinoma?
Conclusion
The combination of AAV-mediated TRAIL gene expression and cisplatin has synergistic therapeutic effects on head and neck cancers and reduces the potential toxicity of cisplatin.
Supporting Evidence
- Cisplatin significantly enhanced AAV-mediated TRAIL expression in cancer cells.
- The combination treatment reduced tumor growth in animal models.
- Cisplatin pretreatment increased the sensitivity of cancer cells to TRAIL-induced apoptosis.
Takeaway
This study found that using a virus to deliver a cancer-fighting protein along with a common chemotherapy drug can work better together than either treatment alone.
Methodology
The study involved treating human head and neck cancer cell lines with AAV/TRAIL and cisplatin, followed by in vitro and in vivo analysis of their effects on cell viability and tumor growth.
Potential Biases
Potential bias in selecting cell lines and animal models that may not fully represent human responses.
Limitations
The study primarily focused on one cell line and may not be generalizable to all head and neck cancers.
Participant Demographics
Nude mice were used for in vivo experiments, with an average weight of about 18 g.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website